McKesson Corp (NYSE:MCK) reported strong fiscal fourth-quarter results with full-year fiscal 2026 adjusted earnings per diluted share increasing by 18% to $39.11, driven primarily by growth in its oncology and multispecialty pharmaceutical segments. Consolidated revenue for the year reached $403 billion, up 12%, while operating cash flow of $6.2 billion exceeded company expectations. The quarter specifically saw adjusted earnings per diluted share rise 16% to $11.69 and revenue increase 6% to $96.3 billion, fueled by broad-based demand across specialty pharmaceutical distribution in North American Pharmaceutical and significant gains in oncology which rose 35% year-over-year. Key highlights included substantial performance in the oncology sector where revenue grew to $12.7 billion and operating profit surged 53% to $385 million, largely supported by PRISM Vision and Core Ventures investments. Conversely, the Medical-Surgical Solutions segment faced headwinds from lower illness season demand for vaccines and testing, resulting in a flat year-over-year revenue and a slight decline in operating profit, though this impact was isolated to that specific division. GLP-1 distribution revenue also saw notable growth, reaching $14 billion in the quarter despite some sequential decline attributed to pricing factors that did not affect overall operating margins. Looking ahead to fiscal 2027, McKesson issued guidance for adjusted earnings per diluted share between $43.80 and $44.60, implying year-over-year growth of 12% to 14%. Management reaffirmed its long-term target for earnings growth at 13% to 16%, with segment-specific outlooks projecting robust expansion in oncology and multispecialty lines between 14.5% and 18.5%. The company also outlined plans to return capital to shareholders through approximately $5 billion in share repurchases alongside free cash flow expectations of $4.5 billion to $4.9 billion for the next fiscal year. Strategically, McKesson is advancing its separation plan for the Medical-Surgical Solutions division, aiming to spin it out as an independent company supported by new debt facilities totaling $2 billion and a strategic minority investment agreement with Apollo Funds for $1.25 billion. CEO Brian Tyler and CFO Britt Vitalone emphasized disciplined portfolio actions and operational momentum as the drivers behind the successful execution of fiscal 2026, positioning the company to maintain steady growth across its core business units despite external market challenges in pricing and specific product demand cycles.